Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Weiyun Z. Ai, James L. Rubenstein et al.|Journal of Investigative Dermatology|2020Cited by 21
Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndromeChen‐Yen Yang, Weiyun Z. Ai, Razan Faraj et al.|Cancer Research|2016Cited by 0
Abstract 798: Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphomaChi-Heng Wu, Weiyun Z. Ai, Chen‐Yen Yang et al.|Cancer Research|2018Cited by 0
Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft ModelsChi-Heng Wu, Weiyun Z. Ai, Chen‐Yen Yang et al.|Blood|2019Cited by 0